Evidence map›Paper›PMID 40840524›Full record

ReviewEndocrine-related cancer2025

Systems biology successes and areas for opportunity in prostate cancer.

Michael V Orman, Laura S Graham, Scott D Cramer, James C Costello

Abstract readReview
In one paragraph

Review in Endocrine-related cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael V OrmanUniversity of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA.
Laura S GrahamUniversity of Colorado Anschutz Medical Campus, Department of Medical Oncology, Aurora, Colorado, USA.
Scott D CramerUniversity of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA.
James C CostelloUniversity of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA.ORCID 0000-0003-3158-9682

Funding

Paul Calabresis Award in Clinical Oncology ResearchK12CA086913 · NCI · UNIVERSITY OF COLORADO DENVER · PI VIRGINIA F. BORGES, Jill E Slansky · 2000 to 2026
$17.8M
Systems analysis of aggressive prostate cancer pathologyU01CA231978 · NCI · UNIVERSITY OF COLORADO DENVER · PI COSTELLO, JAMES CHRISTOPHER, CRAMER, SCOTT D · 2019 to 2023
$3.4M
Androgen Signaling in CaP with loss of MAP3K7 and CHD1R01CA262279 · NCI · UNIVERSITY OF COLORADO DENVER · PI CRAMER, SCOTT D · 2021 to 2025
$1.9M
NCI NIH HHS K12 CA086913NCI NIH HHS R01 CA262279NCI NIH HHS U01 CA231978
6 · The paper itself

Abstract

Systems biology approaches have been applied to prostate cancer to model how individual cellular and molecular components interact to influence cancer development, progression, and treatment responses. The integration of multi-omic experimental data with computational models has provided insights into the molecular characteristics of prostate cancer and emerging treatment strategies that have the potential to improve patient outcomes. Here, we highlight recent advancements that have emerged from systems modeling in prostate cancer. These include descriptions of the molecular landscape of prostate cancer and how genomic alterations inform computational models of disease progression, how evolutionary processes give rise to mechanisms of therapeutic resistance, and the development of innovative treatment strategies such as adaptive therapy. We also highlight current challenges in prostate cancer that can be addressed through systems biology approaches. These include tumor heterogeneity, poor immunotherapy response, a paucity of experimental model systems, and the ongoing translation of computational models for clinical decision making. Leveraging systems biology approaches has the potential to lead to a better understanding of the disease and better patient outcomes in the treatment of prostate cancer.

Indexed as

Prostatic NeoplasmsSystems BiologyAnimalsHumansMaleadaptive therapymolecular landscapeprostate cancersystems biologytumor evolution

Identifiers

PMID40840524
PMCPMC12372069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.